MacroGenics (MGNX)

• Market cap: $252M
• 1 day: -1.25%
• 5 days: 1.8%
• 1 month: 12.5%
• 3 months: 26.92%
• 6 months: 182.86%
• Year to date: 145.96%
• 1 year: 155.48%
• 5 years: -80.96%
• 10 years: -84.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Employees: 293